期刊文献+

应用阿伦膦酸钠治疗动脉粥样硬化过程中护理策略探讨 被引量:1

Care Strategy in the application of alendronate treatment of atherosclerosis process
下载PDF
导出
摘要 目的探讨阿伦膦酸钠治疗动脉粥样硬化研究中护理干预的作用和意义。方法以我院2010年12月-2011年12月纳入应用阿伦膦酸钠治疗动脉粥样硬化研究组的40例患者为研究对象,研究组采用综合护理干预;以我院同期门诊经BMD测定诊断为骨质疏松而服用阿伦磷酸钠治疗的患者40例为对照组,常规告知服药方法及饮食、运动注意事项。统计分析两组患者服药时间、T值和不良反应发生率。结果研究组患者服药次数显著高于对照组(P【0.01),不良反应发声率显著低于对照组(P【0.05);两组患者服药前T值均明显降低,但无显著性差异(P】0.05),治疗后两组患者T值均有明显回升,但研究组患者T值显著高于对照组(P【0.01)。结论护理干预可以有效提高患者的服药依从性,从而提高疗效,降低不良反应,值得临床推广应用。 Objective To investigate the role and significance of alendronate treatment of atherosclerosis research in the nursing intervention.Methods I hospital in December 2010-2011 year December into the application of alendronate in the treatment of atherosclerosis atherosclerosis study group of 40 patients for the study,the research group using the comprehensive nursing intervention;outpatient hospital earlier by BMD determination of 40 patients diagnosed with osteoporosis and taking Allen sodium treatment for the control group,conventional informed medication and diet,exercise attention to matters.The statistical analysis of two groups of patients taking the time T value and the incidence of adverse reactions.Results The number of study group of patients with medication was significantly higher(P<0.01),the sound of adverse reactions was significantly lower than the control group(P<0.05);T value before the taking of the two groups of patients were significantly decreased,but there was no significant difference(P>0.05).Conclusion After treatment,the T values have rebounded significantly,but the T value of the study group patients was significantly higher(P<0.01).
出处 《中国保健营养(下半月)》 2012年第7期2441-2442,共2页 China Health Care & Nutrition
基金 惠州市科研基金项目,专题编号:20110801
关键词 阿伦膦酸钠 动脉粥样硬化 护理 策略 Alendronate Atherosclerosis Care Strategy
  • 相关文献

参考文献5

二级参考文献66

共引文献27

同被引文献21

  • 1甄健存,毛璐.不同途径给药中护理工作安全问题[J].中国护理管理,2007,7(2):11-13. 被引量:14
  • 2徐叔云,魏伟.临床药理学[M].北京:人民卫生出版社,2006:213-214.
  • 3Vielhaber A, Portenoy RK.Advances in cancer pain management [J].Hematol Oncol Clin North Am,2002, 16(3):527-541.
  • 4Mercadante S.Predictive factors and opioid responsi veness in Cancer pain[J].Eur J Cancer, 1998,34(5) : 627-631.
  • 5孙世光,闫荟.高危药品,隘床应用指导[M].北京:人民卫生出版社.2014:315-319.
  • 6Zhang CH,Hsu L,Zou BR,et al.Effects of a pain education program on nurses pain knowledge.Attitudes and Pain Assessment Practices in China[J]. J Pain Symptom Management, 2008,36(6) :616-627.
  • 7Koizumi W, Toma H, Watanabe K, eta l.Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid naive cancer pain patients,starting with 5 mg tablets[J].Jpn J Clin Oncol, 2004,34(3) : 608-614.
  • 8Li JX, Robert GT, Mellar PD, et al. Palliative medicine. Bejing: People" s Health Press, 2005, 171-222.
  • 9Ping D. The clinical observation of slow-released morphine tablets by rectum in the treatment of the patients with moderate to severe cancer pain. Chinese-German J Clin Oncol, 2007, 6:594-595.
  • 10沈娴,蒋霞志.硫酸吗啡控释片直肠给药治疗癌痛的护理[J].实用临床医药杂志(护理版),2008,4(2):24-24. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部